Hashim Mohamed Siraj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hashim Mohamed Siraj has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Husnain Ahmad
S Tentishev Asian Medical Institute Kant Kyrgyzstan
5 shared publications - Masab Ali
Department of Internal Medicine MedStar Health Georgetown University Baltimore Maryland USA
4 shared publications - Nivedita Pant
David Tvildiani Medical University, Tbilisi, Georgia
3 shared publications - Mohammed Alsabri
Pediatric Emergency Medicine, St. Christopher’s Hospital for Children, Philadelphia, USA
2 shared publications Mohammed Usaid
Faculty of Medicine, Ivane Javakhishvili Tbilisi State University, Tbilisi, GEO
2 shared publications- Muhammad Hassan
Department of Internal Medicine Punjab Medical College Faisalabad Punjab Pakistan
2 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science – Atherosclerotic Diseases
- Vol. 11 (1) , 190-197
Trends in pediatric sudden cardiac death-related mortality in the United States from 1999 to 2020: a nationwide CDC WONDER analysis
Introduction: Sudden cardiac death (SCD) in children is rare but devastating, often affecting previously healthy children. Unlike adults, pediatric SCD results from a wide spectrum of uncommon and heterogeneous conditions. Despite recent advancements in understanding and prevention strategies, national data on long-term mortality trends remain limited. Material and methods: We analyzed death certificate data from the CDC WONDER database from 1999 to 2020 for SCD-related mortality in individuals aged 0 to 14 years. Age-adjusted mortality rates (AAMRs) per 100,000, with 95% confidence intervals (CIs) and annual percentage changes (APCs) with 95% CIs, were calculated, stratified by year, sex, race, state, urbanization, and census region. Results: From 1999 until 2020, 30,675 pediatric SCD-related deaths occurred. The AAMR declined from 2.8 per 100,000 population in 1999 to 2.5 (APC = –6.0%, 95% CI: –10.8 to –0.9) in 2001 and further to 2.0 in 2020 (APC = –1.0%, 95% CI: –1.2 to –0.8). AAMRs were consistently higher in males than in females (1999: 3.2 vs. 2.4; 2020: 2.1 vs. 2.0). When stratified by race, non-Hispanic (NH) Black children had the highest AAMRs. Rates declined in all U.S. regions, with the highest rates observed in the Northeast (3.5 to 1.9) and the lowest in the Midwest (1.7 to 1.2). State-level rate disparities were marked, ranging from 4.9 in Mississippi to as low as 1.1 in Maine, Maryland, and Wisconsin. Conclusions: Despite overall declines in SCD-related mortality, significant disparities persist across sex, race, region, and urbanization.
- 28 September 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science – Atherosclerotic Diseases
- Vol. 11 (1) , 190-197
Open AccessTrends in pediatric sudden cardiac death-related mortality in the United States from 1999 to 2020: a nationwide CDC WONDER analysis
Introduction: Sudden cardiac death (SCD) in children is rare but devastating, often affecting previously healthy children. Unlike adults, pediatric SCD results from a wide spectrum of uncommon and heterogeneous conditions. Despite recent advancements in understanding and prevention strategies, national data on long-term mortality trends remain limited. Material and methods: We analyzed death certificate data from the CDC WONDER database from 1999 to 2020 for SCD-related mortality in individuals aged 0 to 14 years. Age-adjusted mortality rates (AAMRs) per 100,000, with 95% confidence intervals (CIs) and annual percentage changes (APCs) with 95% CIs, were calculated, stratified by year, sex, race, state, urbanization, and census region. Results: From 1999 until 2020, 30,675 pediatric SCD-related deaths occurred. The AAMR declined from 2.8 per 100,000 population in 1999 to 2.5 (APC = –6.0%, 95% CI: –10.8 to –0.9) in 2001 and further to 2.0 in 2020 (APC = –1.0%, 95% CI: –1.2 to –0.8). AAMRs were consistently higher in males than in females (1999: 3.2 vs. 2.4; 2020: 2.1 vs. 2.0). When stratified by race, non-Hispanic (NH) Black children had the highest AAMRs. Rates declined in all U.S. regions, with the highest rates observed in the Northeast (3.5 to 1.9) and the lowest in the Midwest (1.7 to 1.2). State-level rate disparities were marked, ranging from 4.9 in Mississippi to as low as 1.1 in Maine, Maryland, and Wisconsin. Conclusions: Despite overall declines in SCD-related mortality, significant disparities persist across sex, race, region, and urbanization.
- Open Access
- 10 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9) , e73488
Acute Mesenteric Ischemia Secondary to Protein C Deficiency: A Case Report
A 43‐year‐old hypertensive male presented with severe abdominal pain, nausea, and constipation due to Protein C deficiency with lupus anticoagulant. CT angiography revealed thrombotic occlusion of mesenteric arteries with collateral circulation. Conservative management with dual anticoagulation and parenteral nutrition achieved clinical improvement without surgery, highlighting thrombophilia's role in mesenteric ischemia.
- 10 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9) , e73488
Open AccessAcute Mesenteric Ischemia Secondary to Protein C Deficiency: A Case Report
A 43‐year‐old hypertensive male presented with severe abdominal pain, nausea, and constipation due to Protein C deficiency with lupus anticoagulant. CT angiography revealed thrombotic occlusion of mesenteric arteries with collateral circulation. Conservative management with dual anticoagulation and parenteral nutrition achieved clinical improvement without surgery, highlighting thrombophilia's role in mesenteric ischemia.
- Open Access
- 1 June 2026
- Published by Springer Nature in Current Emergency and Hospital Medicine Reports
- Vol. 14 (1)
Nutritional Emergencies in Pediatric Emergency Departments: A Global Health Perspective
Purpose of Review: Malnutrition is a significant and global threat in pediatric emergency departments (PEDs), associated with nearly half of all deaths in children under the age of 5. While low and middle-income countries (LMICs) face life-threatening severe acute malnutrition (SAM), high- income countries (HICs) increasingly deal with obesity related complications. This review describes the epidemiology and clinical profiles of nutritional emergencies (NEs) in PEDs, summarizes evidence-based management strategies, including the WHO 10- step protocol and discusses the systemic approaches to strengthen the global PED response. Recent Findings: Globally, an estimated 13.6 million children under 5 suffer from SAM, with hospital case fatality rates ranging from 10 to 30% in many LMICs. Early recognition through visible wasting and anthropometry (MUAC < 11.5 cm) is essential for survival. Immediate PED priorities include treating hypoglycemia, active warming, and providing empiric antibiotics. Regarding fluid resuscitation, evidence from the FEAST trial (which did not specifically enroll children with SAM) showed that aggressive IV boluses increased mortality in febrile children with impaired perfusion, raising concerns about extrapolation to SAM populations who have fragile cardiac function. Current conservative WHO protocols are being re-examined as emerging data suggest liberal rehydration may not consistently increase fluid overload risk. Additionally, electrolyte imbalances and the risk of refeeding syndrome (though more commonly managed in inpatient or ICU settings after initial PED stabilization) require specialized, low-sodium rehydration solutions like ReSoMal. Emerging innovations include point-of-care ultrasound, machine learning risk prediction (AUROC 0.86–0.92), task-shifting to community health workers (improving recovery from 50% to 73%), and simplified protocols reducing RUTF use by 43 sachets per child. Summary: Pediatric emergency departments (PEDs) serve as a critical frontline in the effective management of nutritional emergencies. The success of our intervention hinges on the prompt identification of cases, adherence to tailored stabilization protocols, and a strategic balance between cautious rehydration and the immediate correction of critical metabolic imbalances. By embracing these practices, we can significantly improve outcomes and save lives in vulnerable populations.
- 1 June 2026
- Published by Springer Nature in Current Emergency and Hospital Medicine Reports
- Vol. 14 (1)
Open AccessNutritional Emergencies in Pediatric Emergency Departments: A Global Health Perspective
Purpose of Review: Malnutrition is a significant and global threat in pediatric emergency departments (PEDs), associated with nearly half of all deaths in children under the age of 5. While low and middle-income countries (LMICs) face life-threatening severe acute malnutrition (SAM), high- income countries (HICs) increasingly deal with obesity related complications. This review describes the epidemiology and clinical profiles of nutritional emergencies (NEs) in PEDs, summarizes evidence-based management strategies, including the WHO 10- step protocol and discusses the systemic approaches to strengthen the global PED response. Recent Findings: Globally, an estimated 13.6 million children under 5 suffer from SAM, with hospital case fatality rates ranging from 10 to 30% in many LMICs. Early recognition through visible wasting and anthropometry (MUAC < 11.5 cm) is essential for survival. Immediate PED priorities include treating hypoglycemia, active warming, and providing empiric antibiotics. Regarding fluid resuscitation, evidence from the FEAST trial (which did not specifically enroll children with SAM) showed that aggressive IV boluses increased mortality in febrile children with impaired perfusion, raising concerns about extrapolation to SAM populations who have fragile cardiac function. Current conservative WHO protocols are being re-examined as emerging data suggest liberal rehydration may not consistently increase fluid overload risk. Additionally, electrolyte imbalances and the risk of refeeding syndrome (though more commonly managed in inpatient or ICU settings after initial PED stabilization) require specialized, low-sodium rehydration solutions like ReSoMal. Emerging innovations include point-of-care ultrasound, machine learning risk prediction (AUROC 0.86–0.92), task-shifting to community health workers (improving recovery from 50% to 73%), and simplified protocols reducing RUTF use by 43 sachets per child. Summary: Pediatric emergency departments (PEDs) serve as a critical frontline in the effective management of nutritional emergencies. The success of our intervention hinges on the prompt identification of cases, adherence to tailored stabilization protocols, and a strategic balance between cautious rehydration and the immediate correction of critical metabolic imbalances. By embracing these practices, we can significantly improve outcomes and save lives in vulnerable populations.
- Open Access
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48931
Trends in nontraumatic intestinal perforation-related mortality among adults in the United States from 1999 to 2020: A nationwide CDC WONDER analysis
To characterize mortality trends associated with nontraumatic intestinal perforation (NIP) in the United States, which continue to remain poorly defined. NIP is defined as the loss of continuity of the bowel wall in which external trauma as an etiology has been excluded. NIP is a serious gastrointestinal emergency with limited national mortality trend data, particularly across various demographic and regional subgroups. NIP-related mortality data were extracted from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database from 1999 to 2020. We analyzed age-adjusted mortality rates (AAMR) per 100,000 individuals and annual percent change (APCs) with 95% confidence interval (CI) in patients ≥ 15 years based on gender, race and geographical region. Overall, there were 122,161 NIP-related deaths among patients aged ≥ 15 years, with an increase in AAMR from 1.90 in 1999 to 2.0 in 2009 (APC: 0.19; CI: −0.33 to 0.71), and a gradual increase to 2.40 in 2020 (APC: 1.26; CI: 0.80 to 1.71). AAMR was lower in females compared to males in 1999 (2.0 vs 1.90; CI: 1.90 to 2.0). However, in 2020, AAMR values increased in females (2.20 vs 2.0; CI: 2.40 to 2.60; P < .05). AAMRs were higher in patients reported as non-Hispanic compared to Hispanic/Latinos (2.10 vs 1.50; CI: 2.10 to 2.10; P < .05). Variation in AAMR values across census regions was not significant. NIP-related AAMR was higher in nonmetropolitan than metropolitan areas (2.90 vs 1.90; CI: 2.10 to 2.10; P < .05). NIP-related mortality has risen among patients’ ≥15 years. Higher AAMRs in females, non-Hispanic individuals, and nonmetropolitan populations highlight the need for targeted preventive efforts.
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48931
Open AccessTrends in nontraumatic intestinal perforation-related mortality among adults in the United States from 1999 to 2020: A nationwide CDC WONDER analysis
To characterize mortality trends associated with nontraumatic intestinal perforation (NIP) in the United States, which continue to remain poorly defined. NIP is defined as the loss of continuity of the bowel wall in which external trauma as an etiology has been excluded. NIP is a serious gastrointestinal emergency with limited national mortality trend data, particularly across various demographic and regional subgroups. NIP-related mortality data were extracted from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database from 1999 to 2020. We analyzed age-adjusted mortality rates (AAMR) per 100,000 individuals and annual percent change (APCs) with 95% confidence interval (CI) in patients ≥ 15 years based on gender, race and geographical region. Overall, there were 122,161 NIP-related deaths among patients aged ≥ 15 years, with an increase in AAMR from 1.90 in 1999 to 2.0 in 2009 (APC: 0.19; CI: −0.33 to 0.71), and a gradual increase to 2.40 in 2020 (APC: 1.26; CI: 0.80 to 1.71). AAMR was lower in females compared to males in 1999 (2.0 vs 1.90; CI: 1.90 to 2.0). However, in 2020, AAMR values increased in females (2.20 vs 2.0; CI: 2.40 to 2.60; P < .05). AAMRs were higher in patients reported as non-Hispanic compared to Hispanic/Latinos (2.10 vs 1.50; CI: 2.10 to 2.10; P < .05). Variation in AAMR values across census regions was not significant. NIP-related AAMR was higher in nonmetropolitan than metropolitan areas (2.90 vs 1.90; CI: 2.10 to 2.10; P < .05). NIP-related mortality has risen among patients’ ≥15 years. Higher AAMRs in females, non-Hispanic individuals, and nonmetropolitan populations highlight the need for targeted preventive efforts.
- Open Access
- 3 April 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 188
Assessing the efficacy and safety of transcranial magnetic stimulation and vagus nerve stimulation for drug-resistant epilepsy: A systematic review
Background: Drug-resistant epilepsy (DRE), characterized by inadequate seizure control despite adequate trials of multiple antiepileptic medications, affects a substantial proportion of the global epilepsy population. Recent advances in neuromodulation techniques have demonstrated promise as adjunctive therapeutic approaches for managing treatment-resistant epilepsy. Transcranial magnetic stimulation (TMS) and vagus nerve stimulation (VNS) represent emerging interventions for patients who fail conventional pharmacological management. Methods: A comprehensive search was performed for multiple databases such as PubMed, Cochrane Library, and Google Scholar. Search was done for studies from 1995 to 2024, which will meet our inclusion criteria and exclusion criteria. We selected 36 studies that include randomized controlled trials, observational studies, and retrospective analyses. Our primary outcome is seizure recurrence, and the secondary outcomes are adverse events. Our systematic review is registered in PROSPERO, and its ID is CRD42025629381. Results: Approximately 47% of patients treated with either TMS or VNS were found to have a mean seizure reduction of over 50%, which also contributed to the results of our data interpretation. Even in several institutional studies, it was additionally found that more than 60% of patients showed significant improvements in seizure control. Conclusion: Evidence reported that both TMS and VNS greatly improve seizure control in patients with drug-resistant epilepsy, potentially enhancing quality of life and reducing seizure frequency. A large amount of our findings support the integration of neuromodulation techniques into future treatment regimens for drug-resistant epilepsy, which might be accompanied by calls for future clinical trials.
- 3 April 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 188
Open AccessAssessing the efficacy and safety of transcranial magnetic stimulation and vagus nerve stimulation for drug-resistant epilepsy: A systematic review
Background: Drug-resistant epilepsy (DRE), characterized by inadequate seizure control despite adequate trials of multiple antiepileptic medications, affects a substantial proportion of the global epilepsy population. Recent advances in neuromodulation techniques have demonstrated promise as adjunctive therapeutic approaches for managing treatment-resistant epilepsy. Transcranial magnetic stimulation (TMS) and vagus nerve stimulation (VNS) represent emerging interventions for patients who fail conventional pharmacological management. Methods: A comprehensive search was performed for multiple databases such as PubMed, Cochrane Library, and Google Scholar. Search was done for studies from 1995 to 2024, which will meet our inclusion criteria and exclusion criteria. We selected 36 studies that include randomized controlled trials, observational studies, and retrospective analyses. Our primary outcome is seizure recurrence, and the secondary outcomes are adverse events. Our systematic review is registered in PROSPERO, and its ID is CRD42025629381. Results: Approximately 47% of patients treated with either TMS or VNS were found to have a mean seizure reduction of over 50%, which also contributed to the results of our data interpretation. Even in several institutional studies, it was additionally found that more than 60% of patients showed significant improvements in seizure control. Conclusion: Evidence reported that both TMS and VNS greatly improve seizure control in patients with drug-resistant epilepsy, potentially enhancing quality of life and reducing seizure frequency. A large amount of our findings support the integration of neuromodulation techniques into future treatment regimens for drug-resistant epilepsy, which might be accompanied by calls for future clinical trials.
- Open Access
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46593
Trends and disparities in anencephaly-related early childhood mortality in the United States between 1999 and 2020: A nationwide CDC WONDER analysis
Anencephaly is a severe neural tube defect that affects approximately 1 in every 5250 live births in the United States. This fatal congenital condition is linked to modifiable risk factors, including folic acid deficiency, maternal diabetes, and exposure to teratogenic medications such as certain anti-epileptics. Despite public health efforts to promote folic acid supplementation, disparities in mortality persist. This study aimed to evaluate national trends in anencephaly-related early childhood mortality from 1999 to 2020 using the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. We analyzed death certificate data from the CDC WONDER system to assess trends in anencephaly-related mortality among children from birth to 4 years of age between 1999 and 2020. Age-adjusted mortality rates (AAMRs) per 100,000 population and annual percent changes (APCs) with 95% confidence intervals (CIs) were calculated. Mortality trends were stratified by sex, race/ethnicity, U.S. Census region, state, and 2013 urbanization classification. Between 1999 and 2020, there were 6969 anencephaly-related early childhood deaths in the United States, with 89.7% occurring in medical facilities. The overall AAMR declined from 1.7 in 1999 to 1.5 in 2020 (APC: −0.43; 95% CI: −0.94 to 0.09), with peaks in 2000 and 2012 (AAMR: 1.8). Females consistently had higher AAMRs than males (1.8 vs 1.4). By race, Hispanic individuals had the highest AAMR (2.0), followed by NH White (1.7) and NH Black (1.2), with significant declines among Hispanic and NH Black population. Regionally, the highest AAMR was in the Midwest (1.9), and the lowest in the Northeast (1.0). Among states, South Dakota had the highest (3.2), and Connecticut the lowest (0.5). Noncore metropolitan areas exhibited the highest AAMR (2.1), with varying temporal trends across urbanization levels. Anencephaly-related early childhood mortality has declined in the United States from 1999 to 2020; however, disparities remain. Higher mortality rates persist among Hispanic/Latino populations and in nonmetropolitan areas, highlighting the need for targeted public health interventions. These findings underscore the importance of expanding access to folic acid supplementation, culturally tailored maternal health education, and equitable prenatal care services, especially in underserved communities.
- 26 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46593
Open AccessTrends and disparities in anencephaly-related early childhood mortality in the United States between 1999 and 2020: A nationwide CDC WONDER analysis
Anencephaly is a severe neural tube defect that affects approximately 1 in every 5250 live births in the United States. This fatal congenital condition is linked to modifiable risk factors, including folic acid deficiency, maternal diabetes, and exposure to teratogenic medications such as certain anti-epileptics. Despite public health efforts to promote folic acid supplementation, disparities in mortality persist. This study aimed to evaluate national trends in anencephaly-related early childhood mortality from 1999 to 2020 using the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database. We analyzed death certificate data from the CDC WONDER system to assess trends in anencephaly-related mortality among children from birth to 4 years of age between 1999 and 2020. Age-adjusted mortality rates (AAMRs) per 100,000 population and annual percent changes (APCs) with 95% confidence intervals (CIs) were calculated. Mortality trends were stratified by sex, race/ethnicity, U.S. Census region, state, and 2013 urbanization classification. Between 1999 and 2020, there were 6969 anencephaly-related early childhood deaths in the United States, with 89.7% occurring in medical facilities. The overall AAMR declined from 1.7 in 1999 to 1.5 in 2020 (APC: −0.43; 95% CI: −0.94 to 0.09), with peaks in 2000 and 2012 (AAMR: 1.8). Females consistently had higher AAMRs than males (1.8 vs 1.4). By race, Hispanic individuals had the highest AAMR (2.0), followed by NH White (1.7) and NH Black (1.2), with significant declines among Hispanic and NH Black population. Regionally, the highest AAMR was in the Midwest (1.9), and the lowest in the Northeast (1.0). Among states, South Dakota had the highest (3.2), and Connecticut the lowest (0.5). Noncore metropolitan areas exhibited the highest AAMR (2.1), with varying temporal trends across urbanization levels. Anencephaly-related early childhood mortality has declined in the United States from 1999 to 2020; however, disparities remain. Higher mortality rates persist among Hispanic/Latino populations and in nonmetropolitan areas, highlighting the need for targeted public health interventions. These findings underscore the importance of expanding access to folic acid supplementation, culturally tailored maternal health education, and equitable prenatal care services, especially in underserved communities.
- Open Access
- 30 November 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (12)
Role of Angiotensin Receptor Blockers on Cardiovascular Protection in Marfan Syndrome: A Literature Review
Background and Aims: Marfan Syndrome (MFS) is a hereditary connective tissue disorder with severe cardiovascular complications, including aortic aneurysms and dissections. Current therapies, such as beta‐blockers, have limitations in preventing disease progression. Angiotensin receptor blockers (ARBs) have emerged as a potential therapy due to their modulation of the renin‐angiotensin‐aldosterone system. This review evaluates the evidence of ARBs' cardiovascular benefits in MFS, focusing on their effects on aortic root dilation, stiffness, and clinical outcomes. Methods: A review of literature published between January 2000 and June 2024 was conducted using databases like PubMed, Scopus, Web of Science, and Cochrane Library. Search terms included “Marfan Syndrome,” “Angiotensin Receptor Blockers,” and “cardiovascular outcomes.” Studies assessing the efficacy and safety of ARBs in MFS were included, with their findings summarized descriptively. Results: Preclinical studies demonstrated ARBs' effectiveness in reducing aortic root dilation and stiffness in murine models of MFS. Clinical trials highlighted losartan's ability to slow aortic root dilation in adults and children, with synergistic effects when combined with beta‐blockers. Despite promising results, variability in study designs and dosage regimens limited comparability. A systematic review noted significant TGF‐β inhibition‐related improvements in pediatric patients. However, long‐term safety and optimal dosing require further exploration. Conclusion: ARBs show promise in mitigating cardiovascular complications in MFS by reducing aortic root dilation and improving vascular function. Further research is essential to determine optimal dosing, long‐term efficacy, and combination therapy potential, paving the way for personalized management strategies to improve patient outcomes.
- 30 November 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (12)
Open AccessRole of Angiotensin Receptor Blockers on Cardiovascular Protection in Marfan Syndrome: A Literature Review
Background and Aims: Marfan Syndrome (MFS) is a hereditary connective tissue disorder with severe cardiovascular complications, including aortic aneurysms and dissections. Current therapies, such as beta‐blockers, have limitations in preventing disease progression. Angiotensin receptor blockers (ARBs) have emerged as a potential therapy due to their modulation of the renin‐angiotensin‐aldosterone system. This review evaluates the evidence of ARBs' cardiovascular benefits in MFS, focusing on their effects on aortic root dilation, stiffness, and clinical outcomes. Methods: A review of literature published between January 2000 and June 2024 was conducted using databases like PubMed, Scopus, Web of Science, and Cochrane Library. Search terms included “Marfan Syndrome,” “Angiotensin Receptor Blockers,” and “cardiovascular outcomes.” Studies assessing the efficacy and safety of ARBs in MFS were included, with their findings summarized descriptively. Results: Preclinical studies demonstrated ARBs' effectiveness in reducing aortic root dilation and stiffness in murine models of MFS. Clinical trials highlighted losartan's ability to slow aortic root dilation in adults and children, with synergistic effects when combined with beta‐blockers. Despite promising results, variability in study designs and dosage regimens limited comparability. A systematic review noted significant TGF‐β inhibition‐related improvements in pediatric patients. However, long‐term safety and optimal dosing require further exploration. Conclusion: ARBs show promise in mitigating cardiovascular complications in MFS by reducing aortic root dilation and improving vascular function. Further research is essential to determine optimal dosing, long‐term efficacy, and combination therapy potential, paving the way for personalized management strategies to improve patient outcomes.
- Open Access
- 16 April 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (4) , e70667
Drug‐Induced Renal Vasculitis: Etiology, Pathogenesis, Clinical Manifestations, and Therapeutic Approaches—A Narrative Review
Background and Aims: Drug‐induced renal vasculitis arises from various medications that cause immunological dysregulation or direct vascular damage, leading to inflammation and thrombosis. Clinical manifestations vary widely, from mild constitutional symptoms to severe organ dysfunction. This review aims to thoroughly explore drug‐induced renal vasculitis, focusing on its etiology, pathological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic approaches. This review aims to summarize current knowledge and highlight areas requiring further research.Methods: A comprehensive literature search was conducted using PubMed, MEDLINE, Embase, and Cochrane Library databases. We included peer‐reviewed journal articles and excluded those with insufficient data, poor quality, or lack of relevance. The search terms included combinations of “renal vasculitis,” “drug‐induced vasculitis,” “drug‐related nephritis,” “medication‐induced renal vasculitis,” and specific drug names. An initial search yielded 13,192 articles, of which 13,103 were excluded due to irrelevance, duplication, or outdated information. After full‐text review, 99 peer‐reviewed articles were included.Results: Discontinuation of the offending drug is the primary and most crucial step in managing drug‐induced renal vasculitis. Prognosis is generally more favorable than primary vasculitis, with a high remission rate if the offending drug is stopped early. Due to its rarity, epidemiological data is limited. Diagnosis frequently relies on autoantibodies [antineutrophil cytoplasm antibodies (ANCA), myeloperoxidase (MPO), antinuclear antibody (ANA)] and clinical symptoms, with renal biopsy confirming it. Factors such as high‐dose and long‐term drug use, as well as genetic predispositions, increase the risk.Conclusion: This review provides a comprehensive overview of drug‐induced renal vasculitis, discussing what is known and identifying gaps in understanding. While discontinuing the causative drug remains the cornerstone of management, further research is needed, particularly in developing a formal tool to assess the quality of studies and minimize selection bias.
- 16 April 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (4) , e70667
Open AccessDrug‐Induced Renal Vasculitis: Etiology, Pathogenesis, Clinical Manifestations, and Therapeutic Approaches—A Narrative Review
Background and Aims: Drug‐induced renal vasculitis arises from various medications that cause immunological dysregulation or direct vascular damage, leading to inflammation and thrombosis. Clinical manifestations vary widely, from mild constitutional symptoms to severe organ dysfunction. This review aims to thoroughly explore drug‐induced renal vasculitis, focusing on its etiology, pathological mechanisms, clinical manifestations, diagnostic challenges, and therapeutic approaches. This review aims to summarize current knowledge and highlight areas requiring further research.Methods: A comprehensive literature search was conducted using PubMed, MEDLINE, Embase, and Cochrane Library databases. We included peer‐reviewed journal articles and excluded those with insufficient data, poor quality, or lack of relevance. The search terms included combinations of “renal vasculitis,” “drug‐induced vasculitis,” “drug‐related nephritis,” “medication‐induced renal vasculitis,” and specific drug names. An initial search yielded 13,192 articles, of which 13,103 were excluded due to irrelevance, duplication, or outdated information. After full‐text review, 99 peer‐reviewed articles were included.Results: Discontinuation of the offending drug is the primary and most crucial step in managing drug‐induced renal vasculitis. Prognosis is generally more favorable than primary vasculitis, with a high remission rate if the offending drug is stopped early. Due to its rarity, epidemiological data is limited. Diagnosis frequently relies on autoantibodies [antineutrophil cytoplasm antibodies (ANCA), myeloperoxidase (MPO), antinuclear antibody (ANA)] and clinical symptoms, with renal biopsy confirming it. Factors such as high‐dose and long‐term drug use, as well as genetic predispositions, increase the risk.Conclusion: This review provides a comprehensive overview of drug‐induced renal vasculitis, discussing what is known and identifying gaps in understanding. While discontinuing the causative drug remains the cornerstone of management, further research is needed, particularly in developing a formal tool to assess the quality of studies and minimize selection bias.
- Open Access
- 12 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e82132
Bacterial Histamine as a Therapeutic Target for Abdominal Pain in Irritable Bowel Syndrome: A Literature Review
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain, altered bowel habits, and discomfort. This narrative review explores the current understanding of IBS pathophysiology, diagnosis, and treatment, with a focus on the role of histamine in gastrointestinal disorders. The review summarizes the existing literature from electronic databases and manual searches. Key topics covered include the diagnostic criteria for IBS, mechanisms underlying abdominal pain, role of histamine in gastrointestinal motility, visceral hypersensitivity, and immune system dysregulation, highlighting its potential as a therapeutic target in IBS management. The narrative synthesis of findings provides insights into the complex interplay between gut microbiota, histamine production, and IBS symptomatology. Overall, this review underscores the need for further research to elucidate the mechanisms underlying IBS and histamine-related gastrointestinal disorders, with the ultimate goal of developing tailored therapeutic interventions for individuals affected by these conditions.
- 12 April 2025
- Published by Springer Nature in Cureus
- Vol. 17 (4) , e82132
Open AccessBacterial Histamine as a Therapeutic Target for Abdominal Pain in Irritable Bowel Syndrome: A Literature Review
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain, altered bowel habits, and discomfort. This narrative review explores the current understanding of IBS pathophysiology, diagnosis, and treatment, with a focus on the role of histamine in gastrointestinal disorders. The review summarizes the existing literature from electronic databases and manual searches. Key topics covered include the diagnostic criteria for IBS, mechanisms underlying abdominal pain, role of histamine in gastrointestinal motility, visceral hypersensitivity, and immune system dysregulation, highlighting its potential as a therapeutic target in IBS management. The narrative synthesis of findings provides insights into the complex interplay between gut microbiota, histamine production, and IBS symptomatology. Overall, this review underscores the need for further research to elucidate the mechanisms underlying IBS and histamine-related gastrointestinal disorders, with the ultimate goal of developing tailored therapeutic interventions for individuals affected by these conditions.
- 1 April 2025
- Published by Tsinghua University Press in Brain Science Advances
- Vol. 11 (2)
Therapeutic Approaches in Movement Disorders: A Narrative Review
Movement disorder management and therapy are rapidly evolving, owing to an ever-deeper understanding of disease biology and the discovery of new tools for diagnosis and treatment. With this narrative review, we aim to explore emerging therapeutic approaches for movement disorders, with a focus on Parkinson’s disease (PD) and other movement-related pathological conditions, including Huntington’s disease (HD), essential tremor (ET), and dystonia. This review encompasses preclinical research and human trials, providing a comprehensive overview of the current landscape. Several promising therapeutic strategies have emerged, particularly in the realm of precision medicine for PD associated with GBA and LRRK2 gene mutations. Additionally, innovative immunotherapies and drugs targeting misfolded α-synuclein are under investigation. These approaches have the potential to influence disease progression and improve patient outcomes. The landscape of pharmacological treatments for movement disorders is both complex and diverse, with substantial progress made over the years. While current treatments effectively manage motor symptoms, they fall short of providing a definitive cure and are limited by nonmotor symptoms and potential side effects. Novel techniques, such as gene therapy, stem cell therapy, and infusion therapies, offer promising avenues for future research.
- 1 April 2025
- Published by Tsinghua University Press in Brain Science Advances
- Vol. 11 (2)
Therapeutic Approaches in Movement Disorders: A Narrative Review
Movement disorder management and therapy are rapidly evolving, owing to an ever-deeper understanding of disease biology and the discovery of new tools for diagnosis and treatment. With this narrative review, we aim to explore emerging therapeutic approaches for movement disorders, with a focus on Parkinson’s disease (PD) and other movement-related pathological conditions, including Huntington’s disease (HD), essential tremor (ET), and dystonia. This review encompasses preclinical research and human trials, providing a comprehensive overview of the current landscape. Several promising therapeutic strategies have emerged, particularly in the realm of precision medicine for PD associated with GBA and LRRK2 gene mutations. Additionally, innovative immunotherapies and drugs targeting misfolded α-synuclein are under investigation. These approaches have the potential to influence disease progression and improve patient outcomes. The landscape of pharmacological treatments for movement disorders is both complex and diverse, with substantial progress made over the years. While current treatments effectively manage motor symptoms, they fall short of providing a definitive cure and are limited by nonmotor symptoms and potential side effects. Novel techniques, such as gene therapy, stem cell therapy, and infusion therapies, offer promising avenues for future research.